



July 16, 2024

To,
Listing/ Compliance Department
National Stock Exchange of India Limited
“Exchange Plaza”, Plot No. C/1,
G Block, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
SYMBOL: AARTIPHARM

Dear Sir/ Madam,

Sub: Clarification with respect to our announcement dated May 13, 2024

This is with reference to your email dated July 14, 2024, wherein you have sought clarification on announcement submitted to the Exchange dated May 13, 2024 regarding appointment of Smt. Nehal Garewal as Non-Executive Director of the Company w.e.f. May 13, 2024.

In this regards, we wish to state as follows;

Exchange’s Query: Affirmation that the Director being appointed is not debarred from holding the office of director by virtue of any SEBI order or any other such authority is missing.

Company’s Response: In terms of BSE Circular bearing Reference No. LIST/COMP/14/2018-19 and NSE Circular bearing Reference No. NSE/CML/2018/24 dated June 20, 2018, and based on the confirmation received from Smt. Nehal Garewal, we affirm that she is not debarred from accessing capital markets and/ or restrained from holding the office of director by virtue of any order of the SEBI or any other such authority.

We trust the aforesaid clarification is sufficient. Kindly take the same on your record.

Thanking you,

Yours faithfully,
For **AARTI PHARMALABS LIMITED**

NIKHIL NATU
COMPANY SECRETARY
ICSI M. NO. A27738

AARTI PHARMALABS LIMITED

www.aartipharmalabs.com | CIN : L24100GJ2019PLC110964 | Email : info@aartipharmalabs.com

Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655